Insider Purchases: Inside the Buy
Tag: AnnexonBiosciences
🧬 Annexon, Part 2: The $300,000 Guillain-Barré Cost Matrix and the Pipeline Fuse
Delve into the high-stakes financial and clinical reality of Guillain-Barré Syndrome (GBS)—a devastating neurological emergency carrying a brutal $300,000 cost of standard care. In Part 2 of our Annexon Biosciences (NASDAQ: ANNX) deep dive, we audit how their lead late-stage asset, Tanruprubart, targets C1q neuroinflammation at the source to completely upend healthcare economics, transform patient outcomes, and detonate an 11-day short squeeze trap.
1 comment
|
🧬 Annexon (ANNX): Insiders Buy Millions While Wall Street Bets Against a Breakthrough
Annexon Biosciences is one of the more intriguing biotech setups of 2026. Directors are buying millions of dollars of stock, institutions own virtually the entire float, short interest is elevated, and multiple clinical and regulatory catalysts loom before year-end. High risk? Absolutely. High potential reward? Possibly.